Mathes A, Ibrahim S, Vishal G, McNutt B, Marx S; International Society of Technology Assessment in Health Care. Meeting (19th : 2003 : Canmore, Alta.).

Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 2003; 19: abstract no. 189.

Abbott Laboratories/ University of Illinois at Chicago/Midwestern University, 600 Field Drive, Building J45, Lake Forest, 60045 IL USA Tel: 847-937-3418, Fax: 847-935-1360, E-mail: angelo.mathes@abbott.com

OBJECTIVES: To evaluate health-related-quality-of-life (HRQoL) instruments used in patients with chronic kidney disease (CKD) in terms of: patient characteristics (demographics, diseases, medications), instrument validation (validity, reliability, responsiveness), and instrument dimensions (domains -- physical, mental, social). METHODS: A MEDLINE search limited to human and English was performed using the terms: kidney failure, renal dialysis, hyperparathyroidism, kidney diseases, secondary kidney diseases, peritoneal dialysis, quality of life, and preferences. A total of 1,016 articles were identified. Articles with 'evaluated' HRQoL questionnaires in renal diseases were assessed. 'Evaluation' was defined as questionnaires shown to have validity, reliability, or responsiveness. RESULTS: Fifty-seven HRQoL instruments were used in the CKD population and measured physical, social, and/or mental domains. Fifteen (26%) were evaluated for physical, 11 (19%) for social, and 19 (33%) for mental functioning. The number of instruments in studies with the following patient characteristics were: 33 (58%) ? 65 years of age, 30 (53%) non-Caucasian, 4 (7%) pre-ESKD (stage I, II, or III CKD), 5 (9%) ESKD (stage IV CKD) with transplantation, 56 (98%) ESKD without transplantation (on dialysis), 42 (74%) on peritoneal dialysis, 1 (2%) CKD on iron therapy, 9 (16%) CKD on erythropoetin, and 0 (0%) with CKD and secondary hyperparathyroidism or on vitamin D therapy. DISCUSSION/CONCLUSIONS: Allocation of health care resources are needed to develop HRQoL instruments in specific subpopulations of CKD, namely patients with secondary hyperparathyroidism and patients on IV iron therapy, given that no instrument surfaced in this technology assessment.

Publication Types:

• Meeting Abstracts

Keywords:

• Erythropoietin
• European Continental Ancestry Group
• Health
• Health Status
• Humans
• Hyperparathyroidism, Secondary
• Kidney Diseases
• Kidney Failure, Chronic
• Life
• Peritoneal Dialysis
• Quality of Life
• Questionnaires
• Renal Dialysis
• Technology Assessment, Biomedical
• instrumentation
• hsrmtgs

Other ID:

• GWHSR0004422

UI: 102276107

From Meeting Abstracts